Abstract #3993

Hippocampal Glx in RRMS: A potential therapeutic indicator in fingolimod and injectables

Oun Al-iedani^1,2, Rodney Lea², Jameen Arm¹, Saadallah Ramadan^1,2, and Jeannette Lechner-Scott^2,3,4

¹School of Health Sciences, University of Newcastle, Newcastle, Australia, ²Hunter Medical Research Institute, Newcastle, Australia, ³Department of Neurology, John Hunter Hospital, Newcastle, Australia, ⁴School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

Synopsis

This novel longitudinal study evaluates the hippocampal metabolic and morphologic effects of different DMTs on the RRMS brain. RRMS patients were on fingolimod(N=36), injectables(N=29) and HCs cohort(N=44). MRS was acquired from hippocampus. Findings revealed that fingolimod is associated with a larger statistically significant reduction in hippocampal Glx (p=0.003) compared to injectable (p=0.01) and trending lower compared to HCs (p=0.09). Hippocampal NAA levels showed statistically significant increase in the fingolimod cohort (p≤0.0001) compared to HCs over the 2-years follow-up. These results demonstrate that fingolimod has a more potent effect on hippocampal Glx and NAA profiles than injectable DMTs.

This abstract and the presentation materials are available to members only; a login is required.

Join Here